The Pharmaletter
One To Watch
Mediolanum Farmaceutici
Privately-held Italian pharma group with expertise in both the cardiovascular and oncology areas.
Since 1972, the company has developed four products and registered more than 700 patents for more than 40 nations.
In May 2020, Mediolanum acquired the French immuno-oncology specialist ElsaLys Biotech.
Latest Mediolanum Farmaceutici News
7 May 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze